Acura Pharmaceuticals (NASDAQ:ACUR) has not yet released this specific information in the form of a press release, but I would expect they will soon in some form (currently just up on new NEXAFED website).
This is big news!
My research just uncovered that Acura has reached distribution agreements with the top three national drug wholesalers (McKesson, Cardinal Health, and Amerisource Bergen) and these big three are now distributing Acura's NEXAFED pseudoephedrine tablets to retail drug stores all over the country.
This is extremely significant because these big three represent 85% of all U.S. drug wholesale revenue. These distributors have now given Acura's NEXAFED a national reach that goes well beyond the recently announced direct partnership with drug store chain Kerr Drugs.
Acura has also reached agreement with the the 4th, 5th, 6th, and 7th largest drug wholesale distributors (Morris & Dickson, H.D. Smith, Smith Drug, and NC Mutual Drug) to sale NEXAFED too.
Most have probably missed this big NEXAFED news due to the focus on the recent FDA ruling on OxyContin and the bullish ramifications for Acura's other AVERSION tamper resistant technology for opioid analgesics.
Nexafed® [pseudoephedrine hydrochloride (HCl)] is a 30 mg immediate-release abuse-deterrent decongestant. The next generation pseudoephedrine tablet combines effective nasal-congestion relief with Impede™ technology, a unique polymer matrix that disrupts the conversion of pseudoephedrine into the dangerous drug, methamphetamine. Specifically, the Impede™ technology forms a thick gel when the tablets are dissolved in solvents typically used in the pseudoephedrine extraction or methamphetamine production processes, trapping the pseudoephedrine or converted methamphetamine to prevent its isolation or purification.
Disclosure: I am long ACUR.